

Nexsen successfully lists on ASX

Nexsen Limited (ASX:NXN) (Nexsen or the Company), a nano-biotechnology company developing an innovative point-of-care diagnostic platform, is pleased to announce its successful listing on the Australian Securities Exchange (ASX) with quotation of its securities commencing today.

Key Points:

- Completion of an \$8 million capital raising providing key funding for further development and commercialisation of rapid diagnostics developed on Nexsen's proprietary platform
- Strategic vision is for every person, globally, to benefit from at least one of Nexsen's tests across their lifetime
- Suite of diagnostics being developed on Nexsen's proprietary platform, each targeting a critical unmet need in globally significant markets, including:
 - The GBS Rapid Sensor provides a rapid diagnostic for Group B Streptococcus in expectant mothers, potentially curtailing what is a major cause of death or serious illness in infants
 - Diagnostics for the screening, detection, and ongoing monitoring of various subsets of Acute Kidney Injury and Chronic Kidney Disease
 - Applications in the biosecurity and ag-tech sectors testing for pathogens that cause significant economic losses to agriculture
- Bringing this platform to this stage follows several years of work by Nexsen and research partner and shareholder RMIT University, led by Prof. Vipul Bansal – a world-renowned expert in nanobiotechnology and biosensors
- Australian developed technology at RMIT University's Sir Ian Potter Nanobiosensing Facility in Melbourne
- Significant government and partner support, including from RMIT University, the Australian Research Council (**ARC**) and the Cooperative Research Centres Projects (**CRC-P**) program.

Nexsen's Executive Chairman, Reece O'Connell, commented:

"I am excited to be leading Nexsen at its ASX listing today.

"Nexsen was founded with a bold and ambitious purpose to provide accurate, affordable, timely and accessible testing of diseases and threats that are currently constrained by lab-based systems. Too often, critical health decisions are delayed or compromised because diagnostics rely on slow and costly laboratory systems.

"Our biosensor platform was developed to revolutionise diagnostic testing by delivering laboratory-grade accuracy in a rapid, portable format. We have the potential to transform healthcare by providing a new generation of diagnostics that are faster, more accessible, and capable of reaching patients and communities worldwide.

“Our strategic vision is for every person, globally, to benefit from at least one of our tests in their lifetime.”

\$8 million capital raised in successful IPO

Nexsen has successfully raised \$8 million, supported by several significant institutional investors. The funds will be applied towards further advancing the Company's lead product, the GBS Rapid Sensor, as well as ongoing development of the Nexsen platform and its suite of diagnostic products.

Alpine Capital was the lead manager for the Company's IPO.

A suite of diagnostics targeting critical unmet needs in globally significant markets

Nexsen is developing a suite of diagnostic tools on its proprietary biosensing platform, targeting critical unmet needs in globally significant markets across human health, agriculture, and biosecurity.

Nexsen's most advanced product is the GBS Rapid Sensor, a rapid, lab-grade diagnostic device for the detection of Group B Streptococcus (**GBS**) in expectant mothers. The presence of GBS in the rectum or vagina of a mother at birth can result in a transfer of GBS to newborns, which is a major cause of death or serious illness in infants, as well as contributing to still and pre-term births.

The GBS Rapid Sensor utilises innovative nano-biotechnology to enable timely diagnostics of these important pathogenic bacteria in expectant mothers.

By enabling a point-of-care diagnosis, the GBS Rapid Sensor aims to significantly improve maternal and neonatal health outcomes through early intervention and targeted clinical management. This innovation constitutes a significant advancement in primary healthcare, providing not only a rapid and efficient alternative to the conventional, pathology-based diagnostic methods, but also providing a new opportunity to detect GBS at the point of labour where it is needed the most. This innovation has the potential to influence the prevailing standard-of-care and clinical practices in GBS management.

Nexsen is also developing rapid, point-of-care diagnostics for the screening, detection, and ongoing monitoring of various subsets of Chronic Kidney Disease (**CKD**) and Acute Kidney Injury (**AKI**)

A rapid and accurate diagnosis of a patient's kidney status is critical – whether it be in the ambulance, the Intensive Care Unit, or at home.

CKD is estimated to affect approximately 700 million people globally, with a prevalence ranging between 11% and 14% in countries such as the United States, Australia, the United Kingdom, and India.¹ AKI is particularly prevalent in hospitalised patients, with estimates at 7% of all hospital admissions and 30% of ICU admissions globally. In context, there are approximately 5.7 million ICU admissions in the US annually.²

The availability of a rapid, cost-effective, point-of-care diagnostic for these patients would allow for more frequent monitoring of kidney health and assist in earlier identification and initiation of treatment.

Nexsen's other products in development include diagnostic tools for detecting various pathogens in plants and for identifying Bovine Mastitis in cattle, preventing possible billions of dollars in economic losses across agriculture.

Bringing Australian technologies to market backed by a leading Australian research institution

Nexsen's innovative platform has been developed in partnership with RMIT University at its Sir Ian Potter NanoBioSensing Facility, led by its founding director Prof. Vipul Bansal.

Nexsen is pleased to have Prof. Bansal serve as its Chief Innovation Officer and Chairman of the Nexsen Advisory Board as well as RMIT University being a shareholder in the Company.

Together, Nexsen and RMIT University have won some of Australia's most prestigious competitive grants including an Australian Government's CRC-P grant, for a \$7.7 million project for the GBS Rapid Sensor.

Nexsen is also a participant in the ARC Research Hub for Molecular Biosensors at Point-of-Use (MOBIUS) with its Bovine Mastitis project totalling \$1.6 million. Another \$1.6 million ARC-funded project has been confirmed for further research and development into Nexsen's biosecurity applications.

-ENDS-

ASX release authorised by the Board of Directors.

For more information, please contact:

Corporate Enquiries

Nexsen Limited

e: corporate@nexsen.bio

w: nexsen.bio

Reign Advisory

e: NXN@reignadvisory.com

p: + 61 2 9174 5388

Media Enquiries

Jane Morgan Management

e: info@janemorganmanagement.com.au

Join our Investor Centre

SCAN ME



Footnotes:

1 Frost and Sullivan Market Report, Section 5, Nexsen Prospectus <https://www.nexsen.bio/prospectus>

2 Frost and Sullivan Market Report, Section 5, Nexsen Prospectus <https://www.nexsen.bio/prospectus>

About Nexsen Limited (ASX:NXN)

Nexsen is a nano-biotechnology company developing a next-generation biosensing platform that combines ultra-bright nanoparticles, high-affinity bioreceptors, and modular lateral flow architecture to deliver lab-quality diagnostics in a low-cost, user-friendly format. Nexsen's focus is on applications of its platform technology where there is a significant unmet need in a globally significant market.

Nexsen's lead product is the GBS Rapid Sensor, a rapid, point of care diagnostic tool for the detection of Group B Streptococcus in expectant mothers. Other products in development target various applications across human health, ag-tech, and biosecurity.